Effect of Helicobacter pylori Treatment on Gastroesophageal Reflux Disease (GERD): Meta-Analysis of Randomized Controlled Trials

2011 ◽  
Vol 140 (5) ◽  
pp. S-391 ◽  
Author(s):  
Abdo M. Saad ◽  
Abhishek Choudhary ◽  
Anjana Sathyamurthy ◽  
Hazem T. Hammad ◽  
Murtaza Arif ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Gastroesophageal Reflux Disease ◽  
Gastroesophageal Reflux ◽  
Randomized Controlled Trials ◽  
Reflux Disease ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Randomized Controlled ◽  
Helicobacter Pylori Treatment

scholarly journals Should We Test for Helicobacter Pylori before Treating Gastroesophageal Reflux Disease?

2005 ◽  
Vol 19 (7) ◽  
pp. 425-427 ◽  
Author(s):  
Paul Moayyedi
Keyword(s):  
Helicobacter Pylori ◽  
Gastroesophageal Reflux Disease ◽  
Gastroesophageal Reflux ◽  
Randomized Controlled Trials ◽  
Chronic Gastritis ◽  
Reflux Disease ◽  
Developed Countries ◽  
Controlled Trials ◽  
Randomized Controlled ◽  
H Pylori

Gastroesophageal reflux disease (GERD) is a common problem in childhood. The cause is uncertain but because the incidence of GERD is increasing in developed countries and the prevalence of Helicobacter pylori is decreasing, it has been suggested that this infection protects against GERD. Observational data from 95 children, however, suggest that H pylori eradication does not have a deleterious effect on GERD and this is supported by randomized controlled trials in adults. H pylori eradication may also reduce the efficacy of proton pump inhibitor therapy in infected patients. There are no data from children but inferences from randomized controlled trials in adults suggest this effect is likely to be modest and of uncertain clinical significance. H pylori is an important risk factor for distal gastric adenocarcinoma. It is likely that treating the infection in childhood will prevent pre-malignant changes associated with H pylori from developing in the future. A meta-analysis of four randomized controlled trials suggest that there is a statistically significant impact on healing of chronic gastritis after one year compared with placebo (RR of chronic gastritis: 0.27; 95% CI 0.23 to 0.32). H pylori eradication is therefore recommended in children with GERD that are having an endoscopy. However, when the diagnosis of GERD is being made clinically or by pH monitoring, it is not necessary to screen for H pylori.

scholarly journals The Effects of Baclofen for the Treatment of Gastroesophageal Reflux Disease: A Meta-Analysis of Randomized Controlled Trials

2014 ◽  
Vol 2014 ◽  
pp. 1-8 ◽  
Author(s):  
Shujie Li ◽  
Shengying Shi ◽  
Feng Chen ◽  
Jingming Lin
Keyword(s):  
Gastroesophageal Reflux Disease ◽  
Gastroesophageal Reflux ◽  
Adverse Events ◽  
Randomized Controlled Trials ◽  
Reflux Disease ◽  
Healthy Subjects ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Randomized Controlled ◽  
Esophageal Sphincter

Objectives. Baclofen can relieve gastroesophageal reflux-related symptoms in healthy subjects and gastroesophageal reflux disease (GERD) patients by reducing the incidence of transient lower esophageal sphincter relaxation. This meta-analysis aimed to evaluate the efficacy and safety of baclofen for the treatment of GERD.Methods. We systematically searched randomized controlled trials published prior to November 2013 from PubMed, Medline, Embase, ScienceDirect, ClinicalTrials.gov, and the Cochrane Central Register of Randomized Controlled Trials. We performed a meta-analysis of all eligible trials.Results. Nine studies were identified with a total of 283 GERD patients and healthy subjects. Comparative analysis provided high quality data supporting the ability of baclofen to promote a short-term decrease in the number of reflux episodes per patient, the average length of reflux episodes, and the incidence of transient lower esophageal sphincter relaxation. No serious adverse events or death events were reported, and there were no significant differences in the overall adverse events between baclofen and placebo. All reported side effects of baclofen were of mild-to-moderate intensity, and the drug was well tolerated.Conclusion. Abundant evidence suggests that baclofen may be a useful approach for the treatment of GERD patients; however, a larger well-designed research study would further confirm this recommendation.

scholarly journals The Effect of Helicobacter pylori Eradication in Patients with Gastroesophageal Reflux Disease: A Meta-Analysis of Randomized Controlled Studies

2020 ◽  
Vol 38 (4) ◽  
pp. 261-268 ◽  
Author(s):  
Yan Zhao ◽  
Yarui Li ◽  
Junbi Hu ◽  
Xin Wang ◽  
Mudan Ren ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Gastroesophageal Reflux Disease ◽  
Gastroesophageal Reflux ◽  
Reflux Disease ◽  
English Literature ◽  
Meta Analysis ◽  
Control Group ◽  
Randomized Controlled ◽  
H Pylori ◽  
Relapse Rates

Aim: Helicobacter pylori infection has been established as a definite risk factor for gastric cancer. However, the consequence of H. pylori eradication on the progression of gastroesophageal reflux disease (GERD) remains controversial. The purpose of our study was to investigate the relationship between H. pylori eradication and the development of GERD. Methods: A comprehensive, English literature search was performed from January 1990 to April 2019. Only randomized controlled trials (RCT) that evaluated the effect of H. pylori eradication on GERD were included. Meta-analysis of pooled OR was performed using Review Manger 5.1.7. Results: Seventeen articles with 6,889 subjects (intention-to-treat) that fulfilled the inclusion criteria were finally included in the analysis. Of them, 8 RCTs have the similar study design and inclusion criterion, which included patients with H. pylori infection but without GERD at baseline. The OR for the development of erosive GERD after H. pylori eradication was 1.67 (95% CI 1.12–2.48, p = 0.01). The OR for the development of GERD-related symptoms after H. pylori eradication in eradication group compared with control group was 1.04 (95% CI 0.84–1.29, p = 0.71). In addition, 9 RCTs included patients with both baseline H. pylori infection and GERD. The OR for the healing rates and relapse rates after H. pylori eradication in the H. pylori eradication group vs. control group was 0.92 (95% CI 0.47–1.82, p = 0.82) and 1.12 (95% CI 0.60–2.09, p = 0.71), respectively. Conclusions: Our meta-analyses showed H. pylori eradication may lead to the development of new erosive GERD. However, eradication of H. pylori may affect neither the healing rates nor relapse rates of preexisting GERD.

Sign in / Sign up

Export Citation Format

Share Document